

Next-Generation Breast Cancer Diagnostic and Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (Real-Time PCR, Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Fluorescence In-Situ Hybridization (FISH), Others), By Biomarker (BRCA1/2, ER/PR Receptors, HER-2, Others), By Cancer Sub-Type (Luminal A, Luminal B, Triple Negative/Basal Like, Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched), By Offering (Products, Services), By End User (Hospitals and Clinics, Diagnostic Centers and Reference Labs, Academic and Research Institutes), By Region and Competition, 2020-2030F

Market Report | 2025-04-11 | 187 pages | TechSci Research

AVAILABLE LICENSES:

- Single User License \$4500.00
- Multi-User License \$5500.00
- Custom Research License \$8000.00

Report description:

Global Next-Generation Breast Cancer Diagnostic and Screening Market was valued at USD 4.65 Billion in 2024 and is expected to reach USD 8.53 Billion in the forecast period with a CAGR of 10.61% through 2030. Next-generation breast cancer diagnostic and screening methods refer to advanced and innovative approaches to detecting and diagnosing breast cancer. These methods incorporate cutting-edge technologies, molecular insights, and personalized approaches to improve the accuracy and effectiveness of breast cancer detection, diagnosis, and risk assessment. Next-generation methods enable the molecular subtyping of breast cancer based on specific genetic markers. This subtyping provides insights into the tumor's behavior and

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

helps determine the most appropriate treatment strategy. Common subtypes include hormone receptor-positive, HER2-positive, and triple-negative breast cancer. The increasing incidence of breast cancer worldwide has been a significant driver. As breast cancer rates continue to rise, the demand for advanced diagnostic and screening methods to detect the disease at an early stage has also increased.

Ongoing technological advancements in breast imaging, genetic testing, and molecular diagnostics have improved the accuracy and early detection of breast cancer, driving demand for these technologies. The shift toward personalized medicine has led to an increased demand for diagnostic tests that provide individualized information about a patient's breast cancer subtype and genetic profile. This information guides treatment decisions. Breast cancer awareness campaigns and initiatives promoting early detection have encouraged more women to undergo regular breast cancer screening, contributing to market growth.

Key Market Drivers

Advancements in Technology

Digital mammography has largely supplanted traditional film mammography, offering enhanced image quality, streamlined storage and retrieval, and the capability to manipulate images for improved visualization of breast tissue. As of June 2023, the U.S. Food and Drug Administration reported that 87% of mammography facilities in the United States have adopted 3D mammography systems, also known as breast tomosynthesis, which capture multiple X-ray images from different angles to create a three-dimensional representation of the breast. This technology has been shown to reduce false positives and improve cancer detection, particularly in women with dense breast tissue.

Breast Magnetic Resonance Imaging (MRI) utilizes powerful magnets and radio waves to generate detailed images of breast tissue, proving especially useful for assessing disease extent and detecting tumors in high-risk women. Advanced ultrasound technologies, including elastography and contrast-enhanced ultrasound, offer additional insights into breast lesions, aiding in distinguishing between benign and malignant tumors. Genetic testing has advanced with next-generation sequencing, allowing simultaneous analysis of multiple genes to comprehensively assess mutations associated with breast cancer.

Key Market Challenges

Ethical and Legal Issues

As next-generation diagnostic and screening methods generate large volumes of sensitive patient data, ensuring privacy and data security becomes paramount. Ethical concerns arise regarding the storage, sharing, and protection of patient genetic and medical information. Patients must provide informed consent before undergoing genetic testing or other screening procedures. Ensuring that patients fully understand the implications of the tests, including potential psychological and medical consequences, is an ethical imperative. Concerns about genetic discrimination in employment, insurance, and other areas may deter individuals from undergoing genetic testing. Legal protections against such discrimination are essential to address these concerns. Ethical and legal questions arise about who owns the genetic and medical data generated through screening. This includes issues related to data access, sharing, and commercialization. Next-generation screening technologies must adhere to regulatory standards to ensure safety, accuracy, and efficacy. Navigating the complex regulatory landscape can be a challenge for companies and healthcare providers. Ethical issues related to healthcare equity and access arise when next-generation screening technologies are not equally available to all populations. Disparities in access can lead to unequal health outcomes.

Key Market Trends

Integration of Multi-Omics Data

Multi-omics approaches enable healthcare providers to obtain a detailed profile of breast cancer at the molecular level. This includes information on genetic mutations, gene expression patterns, protein activity, metabolite levels, and epigenetic modifications. Integration of multi-omics data allows for precise molecular subtyping of breast cancer, which helps tailor treatment strategies based on the unique characteristics of each patient's tumor. This approach enhances the effectiveness of targeted therapies and minimizes unnecessary treatments. Multi-omics data analysis can identify biomarkers associated with early-stage breast cancer and risk prediction. This aids in early detection and risk assessment, enabling healthcare providers to intervene at an earlier, more treatable stage. Multi-omics analysis identifies specific molecular targets within breast cancer cells that can be exploited for treatment. This leads to the development of targeted therapies and more effective treatment options. Multi-omics data can be used to monitor a patient's response to treatment over time. Changes in gene expression, protein activity, or metabolite levels can indicate treatment efficacy or the need for therapeutic adjustments.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Key Market Players

- Abbott Laboratories
- Agendia Inc.
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Genomics Co., Ltd.
- CENTOGENE N.V
- Danaher Corporation
- Exact Sciences Corporation
- Hoffmann-La Roche Ltd.
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- Lucence Diagnostics Pte Ltd.

Report Scope:

In this report, the Global Next-Generation Breast Cancer Diagnostic and Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

-□ Next-Generation Breast Cancer Diagnostic and Screening Market, By Technology:

- o Real-Time PCR
- o Immunohistochemistry (IHC)
- o Next-Generation Sequencing (NGS)
- o Fluorescence In-Situ Hybridization (FISH)
- o Others

-□ Next-Generation Breast Cancer Diagnostic and Screening Market, By Biomarker:

- o BRCA1/2
- o ER/PR Receptors
- o HER-2
- o Others

-□ Next-Generation Breast Cancer Diagnostic and Screening Market, By Cancer Sub-Type:

- o Luminal A
- o Luminal B
- o Triple Negative/Basal Like
- o Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched

-□ Next-Generation Breast Cancer Diagnostic and Screening Market, By Offering:

- o Products
- o Services

-□ Next-Generation Breast Cancer Diagnostic and Screening Market, By End User:

- o Hospitals and Clinics
- o Diagnostic Centers, and Reference Labs
- o Academic and Research Institutes

-□ Next-Generation Breast Cancer Diagnostic and Screening Market, By region:

- o North America
 - United States
 - Canada
 - Mexico
- o Asia-Pacific
 - China
 - India

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- South Korea
- Australia
- Japan
- o Europe
- Germany
- France
- United Kingdom
- Spain
- Italy
- o South America
- Brazil
- Argentina
- Colombia
- o Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Next-Generation Breast Cancer Diagnostic and Screening Market.

Available Customizations:

Global Next-Generation Breast Cancer Diagnostic and Screening Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

-□Detailed analysis and profiling of additional market players (up to five).

Table of Contents:

1. Product Overview
 - 1.1. Market Definition
 - 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations
2. Research Methodology
 - 2.1. Objective of the Study
 - 2.2. Baseline Methodology
 - 2.3. Key Industry Partners
 - 2.4. Major Association and Secondary Sources
 - 2.5. Forecasting Methodology
 - 2.6. Data Triangulation & Validation
 - 2.7. Assumptions and Limitations
3. Executive Summary
 - 3.1. Overview of the Market
 - 3.2. Overview of Key Market Segmentations
 - 3.3. Overview of Key Market Players
 - 3.4. Overview of Key Regions/Countries

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 3.5. Overview of Market Drivers, Challenges, Trends
- 4. Voice of Customer
- 5. Global Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
 - 5.1. Market Size & Forecast
 - 5.1.1. By Value
 - 5.2. Market Share & Forecast
 - 5.2.1. By Technology (Real-Time PCR, Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Fluorescence In-Situ Hybridization (FISH), Others)
 - 5.2.2. By Biomarker (BRCA1/2, ER/PR Receptors, HER-2, Others)
 - 5.2.3. By Cancer Sub-Type (Luminal A, Luminal B, Triple Negative/Basal Like, Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched)
 - 5.2.4. By Offering (Products, Services)
 - 5.2.5. By End User (Hospitals and Clinics, Diagnostic Centers, and Reference Labs, Academic and Research Institutes)
 - 5.2.6. By Region
 - 5.2.7. By Company (2024)
 - 5.3. Market Map
- 6. Asia Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
 - 6.1. Market Size & Forecast
 - 6.1.1. By Value
 - 6.2. Market Share & Forecast
 - 6.2.1. By Technology
 - 6.2.2. By Biomarker
 - 6.2.3. By Cancer Sub-Type
 - 6.2.4. By Offering
 - 6.2.5. By End User
 - 6.2.6. By Country
 - 6.3. Asia Pacific: Country Analysis
 - 6.3.1. China Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
 - 6.3.1.1. Market Size & Forecast
 - 6.3.1.1.1. By Value
 - 6.3.1.2. Market Share & Forecast
 - 6.3.1.2.1. By Technology
 - 6.3.1.2.2. By Biomarker
 - 6.3.1.2.3. By Cancer Sub-Type
 - 6.3.1.2.4. By Offering
 - 6.3.1.2.5. By End User
 - 6.3.2. India Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
 - 6.3.2.1. Market Size & Forecast
 - 6.3.2.1.1. By Value
 - 6.3.2.2. Market Share & Forecast
 - 6.3.2.2.1. By Technology
 - 6.3.2.2.2. By Biomarker
 - 6.3.2.2.3. By Cancer Sub-Type
 - 6.3.2.2.4. By Offering
 - 6.3.2.2.5. By End User
 - 6.3.3. Australia Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
 - 6.3.3.1. Market Size & Forecast

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.3.3.1.1. By Value
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Technology
- 6.3.3.2.2. By Biomarker
- 6.3.3.2.3. By Cancer Sub-Type
- 6.3.3.2.4. By Offering
- 6.3.3.2.5. By End User
- 6.3.4. Japan Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
- 6.3.4.1. Market Size & Forecast
- 6.3.4.1.1. By Value
- 6.3.4.2. Market Share & Forecast
- 6.3.4.2.1. By Technology
- 6.3.4.2.2. By Biomarker
- 6.3.4.2.3. By Cancer Sub-Type
- 6.3.4.2.4. By Offering
- 6.3.4.2.5. By End User
- 6.3.5. South Korea Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
- 6.3.5.1. Market Size & Forecast
- 6.3.5.1.1. By Value
- 6.3.5.2. Market Share & Forecast
- 6.3.5.2.1. By Technology
- 6.3.5.2.2. By Biomarker
- 6.3.5.2.3. By Cancer Sub-Type
- 6.3.5.2.4. By Offering
- 6.3.5.2.5. By End User
- 7. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
- 7.1. Market Size & Forecast
- 7.1.1. By Value
- 7.2. Market Share & Forecast
- 7.2.1. By Technology
- 7.2.2. By Biomarker
- 7.2.3. By Cancer Sub-Type
- 7.2.4. By Offering
- 7.2.5. By End User
- 7.2.6. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. France Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.1.1. By Value
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Technology
- 7.3.1.2.2. By Biomarker
- 7.3.1.2.3. By Cancer Sub-Type
- 7.3.1.2.4. By Offering
- 7.3.1.2.5. By End User
- 7.3.2. Germany Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
- 7.3.2.1. Market Size & Forecast

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.3.2.1.1. By Value
- 7.3.2.2. Market Share & Forecast
 - 7.3.2.2.1. By Technology
 - 7.3.2.2.2. By Biomarker
 - 7.3.2.2.3. By Cancer Sub-Type
 - 7.3.2.2.4. By Offering
 - 7.3.2.2.5. By End User
- 7.3.3. Spain Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
 - 7.3.3.1. Market Size & Forecast
 - 7.3.3.1.1. By Value
 - 7.3.3.2. Market Share & Forecast
 - 7.3.3.2.1. By Technology
 - 7.3.3.2.2. By Biomarker
 - 7.3.3.2.3. By Cancer Sub-Type
 - 7.3.3.2.4. By Offering
 - 7.3.3.2.5. By End User
- 7.3.4. Italy Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
 - 7.3.4.1. Market Size & Forecast
 - 7.3.4.1.1. By Value
 - 7.3.4.2. Market Share & Forecast
 - 7.3.4.2.1. By Technology
 - 7.3.4.2.2. By Biomarker
 - 7.3.4.2.3. By Cancer Sub-Type
 - 7.3.4.2.4. By Offering
 - 7.3.4.2.5. By End User
- 7.3.5. United Kingdom Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
 - 7.3.5.1. Market Size & Forecast
 - 7.3.5.1.1. By Value
 - 7.3.5.2. Market Share & Forecast
 - 7.3.5.2.1. By Technology
 - 7.3.5.2.2. By Biomarker
 - 7.3.5.2.3. By Cancer Sub-Type
 - 7.3.5.2.4. By Offering
 - 7.3.5.2.5. By End User
- 8. North America Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
 - 8.1. Market Size & Forecast
 - 8.1.1. By Value
 - 8.2. Market Share & Forecast
 - 8.2.1. By Technology
 - 8.2.2. By Biomarker
 - 8.2.3. By Cancer Sub-Type
 - 8.2.4. By Offering
 - 8.2.5. By End User
 - 8.2.6. By Country
 - 8.3. North America: Country Analysis
 - 8.3.1. United States Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
 - 8.3.1.1. Market Size & Forecast

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.3.1.1.1. By Value
- 8.3.1.2. Market Share & Forecast
 - 8.3.1.2.1. By Technology
 - 8.3.1.2.2. By Biomarker
 - 8.3.1.2.3. By Cancer Sub-Type
 - 8.3.1.2.4. By Offering
 - 8.3.1.2.5. By End User
- 8.3.2. Mexico Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
 - 8.3.2.1. Market Size & Forecast
 - 8.3.2.1.1. By Value
 - 8.3.2.2. Market Share & Forecast
 - 8.3.2.2.1. By Technology
 - 8.3.2.2.2. By Biomarker
 - 8.3.2.2.3. By Cancer Sub-Type
 - 8.3.2.2.4. By Offering
 - 8.3.2.2.5. By End User
- 8.3.3. Canada Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
 - 8.3.3.1. Market Size & Forecast
 - 8.3.3.1.1. By Value
 - 8.3.3.2. Market Share & Forecast
 - 8.3.3.2.1. By Technology
 - 8.3.3.2.2. By Biomarker
 - 8.3.3.2.3. By Cancer Sub-Type
 - 8.3.3.2.4. By Offering
 - 8.3.3.2.5. By End User
- 9. South America Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
 - 9.1. Market Size & Forecast
 - 9.1.1. By Value
 - 9.2. Market Share & Forecast
 - 9.2.1. By Technology
 - 9.2.2. By Biomarker
 - 9.2.3. By Cancer Sub-Type
 - 9.2.4. By Offering
 - 9.2.5. By End User
 - 9.2.6. By Country
 - 9.3. South America: Country Analysis
 - 9.3.1. Brazil Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
 - 9.3.1.1. Market Size & Forecast
 - 9.3.1.1.1. By Value
 - 9.3.1.2. Market Share & Forecast
 - 9.3.1.2.1. By Technology
 - 9.3.1.2.2. By Biomarker
 - 9.3.1.2.3. By Cancer Sub-Type
 - 9.3.1.2.4. By Offering
 - 9.3.1.2.5. By End User
 - 9.3.2. Argentina Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
 - 9.3.2.1. Market Size & Forecast

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.3.2.1.1. By Value
- 9.3.2.2. Market Share & Forecast
 - 9.3.2.2.1. By Technology
 - 9.3.2.2.2. By Biomarker
 - 9.3.2.2.3. By Cancer Sub-Type
 - 9.3.2.2.4. By Offering
 - 9.3.2.2.5. By End User
- 9.3.3. Colombia Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
 - 9.3.3.1. Market Size & Forecast
 - 9.3.3.1.1. By Value
 - 9.3.3.2. Market Share & Forecast
 - 9.3.3.2.1. By Technology
 - 9.3.3.2.2. By Biomarker
 - 9.3.3.2.3. By Cancer Sub-Type
 - 9.3.3.2.4. By Offering
 - 9.3.3.2.5. By End User
- 10. Middle East and Africa Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
 - 10.1. Market Size & Forecast
 - 10.1.1. By Value
 - 10.2. Market Share & Forecast
 - 10.2.1. By Technology
 - 10.2.2. By Biomarker
 - 10.2.3. By Cancer Sub-Type
 - 10.2.4. By Offering
 - 10.2.5. By End User
 - 10.2.6. By Country
 - 10.3. MEA: Country Analysis
 - 10.3.1. South Africa Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
 - 10.3.1.1. Market Size & Forecast
 - 10.3.1.1.1. By Value
 - 10.3.1.2. Market Share & Forecast
 - 10.3.1.2.1. By Technology
 - 10.3.1.2.2. By Biomarker
 - 10.3.1.2.3. By Cancer Sub-Type
 - 10.3.1.2.4. By Offering
 - 10.3.1.2.5. By End User
 - 10.3.2. Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
 - 10.3.2.1. Market Size & Forecast
 - 10.3.2.1.1. By Value
 - 10.3.2.2. Market Share & Forecast
 - 10.3.2.2.1. By Technology
 - 10.3.2.2.2. By Biomarker
 - 10.3.2.2.3. By Cancer Sub-Type
 - 10.3.2.2.4. By Offering
 - 10.3.2.2.5. By End User
 - 10.3.3. UAE Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
 - 10.3.3.1. Market Size & Forecast

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.3.3.1.1. By Value
- 10.3.3.2. Market Share & Forecast
 - 10.3.3.2.1. By Technology
 - 10.3.3.2.2. By Biomarker
 - 10.3.3.2.3. By Cancer Sub-Type
 - 10.3.3.2.4. By Offering
 - 10.3.3.2.5. By End User
- 11. Market Dynamics
 - 11.1. Drivers
 - 11.2. Challenges
- 12. Market Trends & Developments
 - 12.1. Recent Developments
 - 12.2. Product Launches
 - 12.3. Mergers & Acquisitions
- 13. Global Next-Generation Breast Cancer Diagnostic and Screening Market: SWOT Analysis
- 14. Porter's Five Forces Analysis
 - 14.1. Competition in the Industry
 - 14.2. Potential of New Entrants
 - 14.3. Power of Suppliers
 - 14.4. Power of Customers
 - 14.5. Threat of Substitute Product
- 15. PESTLE Analysis
- 16. Competitive Landscape
 - 16.1. Abbott Laboratories
 - 16.1.1. Business Overview
 - 16.1.2. Company Snapshot
 - 16.1.3. Products & Services
 - 16.1.4. Financials (In case of listed companies)
 - 16.1.5. Recent Developments
 - 16.1.6. SWOT Analysis
 - 16.2. Agendia Inc.
 - 16.3. Agilent Technologies, Inc.
 - 16.4. Bio-Rad Laboratories, Inc.
 - 16.5. BGI Genomics Co., Ltd.
 - 16.6. CENTOGENE N.V.
 - 16.7. Danaher Corporation
 - 16.8. Exact Sciences Corporation
 - 16.9. F. Hoffmann-La Roche Ltd.
 - 16.10. Illumina, Inc.
 - 16.11. Thermo Fisher Scientific Inc.
 - 16.12. Lucence Diagnostics Pte Ltd.
- 17. Strategic Recommendations
- 18. About Us & Disclaimer

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Next-Generation Breast Cancer Diagnostic and Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (Real-Time PCR, Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Fluorescence In-Situ Hybridization (FISH), Others), By Biomarker (BRCA1/2, ER/PR Receptors, HER-2, Others), By Cancer Sub-Type (Luminal A, Luminal B, Triple Negative/Basal Like, Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched), By Offering (Products, Services), By End User (Hospitals and Clinics, Diagnostic Centers and Reference Labs, Academic and Research Institutes), By Region and Competition, 2020-2030F

Market Report | 2025-04-11 | 187 pages | TechSci Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4500.00
	Multi-User License	\$5500.00
	Custom Research License	\$8000.00
		VAT
		Total

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

□** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-06-09"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com